News
A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...
"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...
As the obesity rate among people with type 1 diabetes rises, patients are taking popular weight loss drugs like Ozempic—and ...
11h
Zacks Investment Research on MSNLLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...
Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...
ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...
Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...
A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...
Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...
Eli Lilly and Co. is suing an Indianapolis-based weight-loss clinic it says is improperly selling Lilly’s hugely popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results